These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 38603652)

  • 1. Regorafenib in Patients With Solid Tumors With
    Sahai V; Rothe M; Mangat PK; Garrett-Mayer E; Suhag V; Dib EG; Mehmi I; Kadakia KC; Pisick E; Duvivier HL; Le P; Li R; Michelin DP; Wilcox RE; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
    JCO Precis Oncol; 2024 Apr; 8():e2300527. PubMed ID: 38603652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With
    Meric-Bernstam F; Rothe M; Mangat PK; Garrett-Mayer E; Gutierrez R; Ahn ER; Cannon TL; Powell S; Krauss JC; Reynolds CM; von Mehren M; Behl D; Calfa CJ; Duvivier HL; Kaplan HG; Livingston MB; Sharma MR; Urba WJ; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
    JCO Precis Oncol; 2023 Sep; 7():e2300385. PubMed ID: 38096472
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With
    Rohatgi N; Rothe M; Mangat PK; Garrett-Mayer E; Meric-Bernstam F; Pisick E; Alese OB; Reynolds CM; Thota R; Vaccaro GM; von Mehren M; Arend RC; Chiu VK; Duvivier HL; Gold PJ; Hack K; Marr AS; Winer A; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
    JCO Precis Oncol; 2023 Sep; 7():e2300279. PubMed ID: 38039429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Talazoparib in Patients With Solid Tumors With
    Srkalovic G; Rothe M; Mangat PK; Garrett-Mayer E; Ahn ER; Brouse G; Chan J; Mehmi I; Khalil M; Duvivier HL; Gaba A; Leuva H; Thota R; Yost KJ; Grantham GN; Gregory A; Hinshaw DC; Halabi S; Schilsky RL
    JCO Precis Oncol; 2024 Jun; 8():e2400026. PubMed ID: 38865672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cobimetinib Plus Vemurafenib in Patients With Colorectal Cancer With
    Klute KA; Rothe M; Garrett-Mayer E; Mangat PK; Nazemzadeh R; Yost KJ; Duvivier HL; Ahn ER; Cannon TL; Alese OB; Krauss JC; Thota R; Calfa CJ; Denlinger CS; O'Lone R; Halabi S; Grantham GN; Schilsky RL
    JCO Precis Oncol; 2022 Nov; 6():e2200191. PubMed ID: 36409971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sunitinib in Patients With Breast Cancer With
    Calfa CJ; Rothe M; Mangat PK; Garrett-Mayer E; Ahn ER; Burness ML; Gogineni K; Rohatgi N; Al Baghdadi T; Conlin A; Gaba A; Hamid O; Krishnamurthy J; Gavini NJ; Gold PJ; Rodon J; Rueter J; Thota R; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
    JCO Precis Oncol; 2024 Feb; 8():e2300513. PubMed ID: 38354330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With
    Cannon TL; Rothe M; Mangat PK; Garrett-Mayer E; Chiu VK; Hwang J; Vijayvergia N; Alese OB; Dib EG; Duvivier HL; Klute KA; Sahai V; Ahn ER; Bedano P; Behl D; Sinclair S; Thota R; Urba WJ; Yang ES; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
    J Clin Oncol; 2024 May; ():JCO2302078. PubMed ID: 38748939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study.
    Duvivier HL; Rothe M; Mangat PK; Garrett-Mayer E; Ahn ER; Al Baghdadi T; Alva AS; Dublis SA; Cannon TL; Calfa CJ; Li R; Behl D; Chiu VK; Gold PJ; Marr AS; Mileham KF; Powell SF; Rodon J; Thota R; Grantham GN; Gregory A; Hinshaw DC; Halabi S; Schilsky RL
    J Clin Oncol; 2023 Nov; 41(33):5140-5150. PubMed ID: 37561967
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Palbociclib in Patients With Soft Tissue Sarcoma With
    Schuetze S; Rothe M; Mangat PK; Garrett-Mayer E; Meric-Bernstam F; Calfa CJ; Farrington LC; Livingston MB; Wentzel K; Behl D; Kier Y; Marr AS; von Mehren M; Press JZ; Thota R; Grantham GN; Gregory A; Hinshaw DC; Halabi S; Schilsky RL
    JCO Precis Oncol; 2024 Jul; 8():e2400219. PubMed ID: 39013131
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With
    Ganti AK; Rothe M; Mangat PK; Garrett-Mayer E; Dib EG; Duvivier HL; Ahn ER; Behl D; Borghaei H; Balmanoukian AS; Gaba A; Li R; Osei-Boateng K; Thota R; Grantham GN; Gregory A; Halabi S; Schilsky RL
    JCO Precis Oncol; 2023 Jun; 7():e2300041. PubMed ID: 37315265
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With
    Ahn ER; Rothe M; Mangat PK; Garrett-Mayer E; Ali-Ahmad HM; Chan J; Maitland ML; Patel SR; Reese Z; Balmanoukian AS; Drescher CW; Li R; Tsimberidou AM; Leath CA; O'Lone R; Grantham GN; Halabi S; Schilsky RL
    JCO Precis Oncol; 2023 Apr; 7():e2200609. PubMed ID: 37027810
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Fisher JG; Tait D; Garrett-Mayer E; Halabi S; Mangat PK; Schink JC; Alvarez RH; Veljovich D; Cannon TL; Crilley PA; Pollock T; Calfa CJ; Al Baghdadi T; Thota R; Fleming N; Cotta JA; Rygiel AL; Warren SL; Schilsky RL
    Target Oncol; 2020 Dec; 15(6):733-741. PubMed ID: 33090333
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Palbociclib in Patients With Non-Small-Cell Lung Cancer With
    Ahn ER; Mangat PK; Garrett-Mayer E; Halabi S; Dib EG; Haggstrom DE; Alguire KB; Calfa CJ; Cannon TL; Crilley PA; Gaba AG; Marr AS; Sangal A; Thota R; Antonelli KR; Islam S; Rygiel AL; Bruinooge SS; Schilsky RL
    JCO Precis Oncol; 2020 Nov; 4():757-766. PubMed ID: 35050752
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.
    Bekaii-Saab TS; Ou FS; Ahn DH; Boland PM; Ciombor KK; Heying EN; Dockter TJ; Jacobs NL; Pasche BC; Cleary JM; Meyers JP; Desnoyers RJ; McCune JS; Pedersen K; Barzi A; Chiorean EG; Sloan J; Lacouture ME; Lenz HJ; Grothey A
    Lancet Oncol; 2019 Aug; 20(8):1070-1082. PubMed ID: 31262657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).
    García-Alfonso P; Benavides M; Falcó E; Muñoz A; Gómez A; Sastre J; Rivera F; Montagut C; Salgado M; López-Ladrón A; López R; Ruiz de Mena I; Durán G; Aranda E;
    Oncologist; 2018 Nov; 23(11):1271-e128. PubMed ID: 30120161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
    Alva AS; Mangat PK; Garrett-Mayer E; Halabi S; Hansra D; Calfa CJ; Khalil MF; Ahn ER; Cannon TL; Crilley P; Fisher JG; Haslem DS; Shrestha S; Antonelli KR; Butler NL; Warren SL; Rygiel AL; Ranasinghe S; Bruinooge SS; Schilsky RL
    J Clin Oncol; 2021 Aug; 39(22):2443-2451. PubMed ID: 33844595
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study.
    Duffaud F; Mir O; Boudou-Rouquette P; Piperno-Neumann S; Penel N; Bompas E; Delcambre C; Kalbacher E; Italiano A; Collard O; Chevreau C; Saada E; Isambert N; Delaye J; Schiffler C; Bouvier C; Vidal V; Chabaud S; Blay JY;
    Lancet Oncol; 2019 Jan; 20(1):120-133. PubMed ID: 30477937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With
    Gupta R; Meric-Bernstam F; Rothe M; Garrett-Mayer E; Mangat PK; D'Andre S; Ahn ER; O'Lone R; Halabi S; Grantham GN; Schilsky RL
    JCO Precis Oncol; 2022 Oct; 6():e2200306. PubMed ID: 36315917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
    Kang YK; George S; Jones RL; Rutkowski P; Shen L; Mir O; Patel S; Zhou Y; von Mehren M; Hohenberger P; Villalobos V; Brahmi M; Tap WD; Trent J; Pantaleo MA; Schöffski P; He K; Hew P; Newberry K; Roche M; Heinrich MC; Bauer S
    J Clin Oncol; 2021 Oct; 39(28):3128-3139. PubMed ID: 34343033
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17.
    Yeh CN; Chen MH; Chen YY; Yang CY; Yen CC; Tzen CY; Chen LT; Chen JS
    Oncotarget; 2017 Jul; 8(27):44121-44130. PubMed ID: 28487491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.